FDG-PET Offers Superior Melanoma Staging and Follow-up

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

TORONTO--Patients with high-risk melanoma may benefit from use of whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for primary staging, researchers from the University of Frankfurt/Main reported at the 45th Annual Meeting of the Society of Nuclear Medicine.

TORONTO--Patients with high-risk melanoma may benefit from use of whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for primary staging, researchers from the University of Frankfurt/Main reported at the 45th Annual Meeting of the Society of Nuclear Medicine.

Improved Diagnostic Accuracy

"We find an improved diagnostic accuracy using FDG-PET to assess patients," said Dr. Andreas Hertel, Department of Nuclear Medicine, University Hospital, Frankfurt. "The sensitivity and specificity of PET is superior, particularly in high-risk patients with metastases."

This prospective study included 100 patients with confirmed high-risk malignant melanoma. They were evaluated using whole-body FDG-PET and conventional diagnostic imaging (MRI of the brain; x-ray of the chest; CT of the thorax, abdomen, and pelvis; ultrasound of the abdomen; high-resolution lymph node sonography; and skeletal scintigraphy).

Fifty-two of the patients were studied at primary diagnosis of their disease and 48 at follow-up with suspicion of recurrence. Every identified lesion was confirmed by histology.

For the patients with a primary diagnosis, PET was 100% sensitive in detecting metastases (see figure), while conventional imaging did not identify any of the nine metastatic lesions. In the patients with suspected recurrence, 121 lesions were detected, 111 (92%) by PET and 69 (57%) by conventional imaging. The conventional methods did not identify all patients with progression and detected significantly fewer metastases.

Results Depended on Site

Results also depended on specific sites (see table): While PET yielded a higher sensitivity in detecting cervical metastases (100% vs 66.6%) and abdominal metastases (100% vs 26.6%), CT proved to be superior in detecting small lung metastases (87% vs 69.6%).

"We demonstrated that we can find very small lesions with a high sensitivity and specificity compared to CT, especially in the primary staging of high-risk patients," Dr. Hertel said. "We believe that PET should replace CT as the front-line procedure in staging patients."

Speaking at a press conference held in conjunction with the meeting, lead author Richard P. Baum, MD, chair of the Bad Berka PET Center, said: "If we detect lesions with FDG-PET and plan to operate, then we need CT and/or MRI for anatomic information and surgical planning, but we don’t need those tests for staging a patient with malignant melanoma as the front-line procedure."

Dr. Baum also pointed out that use of PET can save considerable time. "We can do a whole-body FDG-PET scan in one hour," he said, "compared to multiple days in the hospital for a standard diagnostic workup."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Experts on myeloma
Related Content